ALFA FinderNSE filing, NSE: ERIS. Summary written from the filing by ALFA Finder's alert engine.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,261.60
- Market cap
- ₹17,503 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 24.7×Sector 43.4×
- Promoter holding
- 54.74%+0.60% QoQ
- FII holding
- 5.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Annual General Meeting
Eris Lifesciences has issued a postal ballot notice seeking members' approval to appoint Mr. Akhil Awasthi as Independent Director for five years from 26 September 2026. E-voting runs 6 November to 5 December 2026.
- Execution
- 26 September 2026 to 25 September 2031
Eris Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.
Eris Lifesciences Q2 FY27 Results: Net Profit ₹187.1 Cr, Up 39.1% YoY
Eris Lifesciences Ltd reported revenue from operations of ₹892.4 Cr (+12.6% YoY) and net profit of ₹187.1 Cr (+39.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹187.1 Cr · +39.1% YoY
Eris Lifesciences Board Meeting Date
Eris Lifesciences has scheduled a board meeting for October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ending September.
Eris Lifesciences Other Announcement
Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Eris Lifesciences Debt & Borrowing: ₹1,250 Cr
Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.
- Value
- ₹1,250 Cr
Other price movement clarification announcements
All →Banka Bioloo Price Movement Clarification
Banka BioLoo responded to NSE's query on a significant price movement, stating the spurt was market-driven. The company says it has made all required disclosures and has no pending price-sensitive announcement.
Vaibhav Vyapaar Price Movement Clarification
Vaibhav Vyapaar responded to NSE's surveillance query on a significant share price movement. The company states no undisclosed material event exists and the move appears market-driven.
TVS Electronics Price Movement Clarification
TVS Electronics Limited responded to NSE's query on a significant increase in trading volume, stating it has no pending information to disclose under Regulation 30. The response confirms all price-sensitive information has already been disclosed.
Moving Media Entertainment Price Movement Clarification
Moving Media Entertainment clarified to NSE a significant share price movement, stating it has no unpublished price-sensitive information. The company attributes the movement to market conditions and external factors.
Aerpace Industries Price Movement Clarification
Aerpace Industries clarified that recent significant movement in its share price is market-driven. The company confirmed it has no undisclosed material information impacting the stock price.
Sotac Pharmaceuticals Price Movement Clarification
Sotac Pharmaceuticals clarified that recent share price movements are entirely market-driven. The company confirmed it has disclosed all material information in compliance with SEBI regulations.